Munich Medical Service offers its patients a full range of urological diagnostics in the leading university and specialized clinics in Munich
Due to the synergistic use in clinical practice of both traditional medicine methods and completely new, innovative developments, Munich clinics are widely known not only among patients and doctors in Germany, but also abroad. A combined approach to the diagnosis and treatment of various diseases guarantees our patients the highest quality examination and effective treatment.
All the specialists offered by our company are doctors of the highest category who carry out a complete diagnosis and treatment of the entire spectrum of diseases of the urogenital tract
During the inspection, the latest technical equipment is used, for example:
Sonoline S2000, which differs from traditional devices in several innovative methods. These include a technology called dynamic tissue contrast (TCETM), which allows you to obtain images by increasing the differentiation of tissues (by highlighting the edges of the tissue and reducing noise in the image)
Mindray M5 with Smart 3D Technology
Urological preventive examination includes the following items:
- Medical history
- Clinical examination
- Transrectal Sonography (TRUS)
- Laboratory blood tests, including determination of the hormonal profile, PSA level and the latest tumor markers of the prostate and bladder
- Ultrasound of the kidneys and adrenal glands
- Ultrasound of the bladder
- Ultrasound scrotum
- Trasrectal 3D ultrasound of the prostate
If necessary, the most advanced diagnostic methods are used:
High-field magnetic resonance imaging (3 T MRI)
Magnetic Resonance Spectroscopy (MRS)
CEUS contrast ultrasound
Fusion Prostate Biopsy
PET-CT with radioactive choline
PSMA PET-CT is the latest diagnostic study for recurrent prostate cancer
German medicine relies on a safe and non-invasive definition of cancer. A number of studies have been developed that, with a high degree of certainty, make it possible to identify high-risk patients and use invasive research methods to confirm the diagnosis only in this group.
For example, a laboratory blood test includes the most advanced biomarkers that are used to diagnose prostate cancer. These include the PCA3-mRNA Score, a molecular genetic test that has exceptional specificity for prostate cancer for the timely and accurate detection of carcinoma. The higher the PCA3 value, the more likely that the size of the tumor exceeds critical. A low PCA3 indicates minimal risk of prostate cancer. The analysis is carried out by taking and processing blood.
PCa-3 is a genetic tumor marker, a prostate-specific gene located on chromosome 9. In cases of prostate carcinoma in 95% of cases there is an increase in its expression by 60-100 times. For the accuracy of the calculation of the values in each case, the ratio of PCa-3 mRNA to PCA-mRNA is calculated. If the obtained ratio exceeds 35, the likelihood of having prostate carcinoma increases and it is recommended to do a biopsy to verify the diagnosis.
The level of PCa-3 does not correlate with the size of the prostate, but with the volume and degree of malignancy of the tumor. At the moment, studies are underway that will allow in the future based on this indicator to make a forecast of the course of the disease.
Another tumor marker that allows non-invasive detection of bladder cancer is UBC, a specific antigen of bladder cancer, the level of which is determined in the urine.
The latest development in ultrasound examination of the prostate is elstography, which allows to determine the tumor foci of their borders and the depth of occurrence, as well as to make an approximate differentiation of the benign process.
For histological diagnosis of prostate cancer, a prostate biopsy may be proposed under local anesthesia or sedation (modern anesthesia technique). Sampling is carried out transrectally, that is, through the rectum under the control of ultrasound.